Ten-year Single Center Experience With Colistin Therapy in NICU
- 5 October 2023
- journal article
- research article
- Published by Wolters Kluwer Health in The Pediatric Infectious Disease Journal
- Vol. 43 (2) , 165-169
Abstract
Background: Colistin, a cationic polypeptide antibiotic of the polymyxin class has come back into use due to its potent antimicrobial activity against multidrug-resistant Gram-negative bacteria and the lack of new antibiotics. The purpose of this study was to assess the critically ill infants treated with colistin in our neonatal intensive care unit and to identify predisposing factors for the emergence of acute kidney injury (AKI) following colistin treatment. Methods: This was a retrospective case-control study that included infants with proven or suspected nosocomial infections in the neonatal intensive care unit of a University Hospital between January 2012 and March 2022. Over the same time period, the clinical and laboratory characteristics and outcomes of patients who received antibiotic combination with colistin were compared to patients who received antibiotic combination without colistin. Results: A total of 77 patients were in the colistin group (ColG) and 77 patients were in the control group. The demographic and clinical characteristics of the study groups were similar. In the ColG compared to the control group, hyponatremia, hypokalemia, hypophosphatemia, hypomagnesia and AKI were all more prevalent (P < 0.05). The most important finding in our study was the higher incidence of AKI and mortality in ColG, as well as the increasing nephrotoxic effect of other medications when used in conjunction with colistin. Conclusion: During colistin therapy, newborn infants must be closely monitored for AKI. Clinicians should be aware of an increased incidence of hyponatremia, hypokalemia, hypophosphatemia, hypomagnesia, AKI and its consequences in infants given colistin. As awareness increases, harmful effects will decrease.Keywords
This publication has 29 references indexed in Scilit:
- Intravenous Colistin Administration in NeonatesThe Pediatric Infectious Disease Journal, 2011
- Renal and neurological side effects of colistin in critically ill patientsAnnals of Intensive Care, 2011
- Colistin in the 21st centuryCurrent Opinion in Infectious Diseases, 2009
- Differential roles of dihydropyridine calcium antagonist nifedipine, nitrendipine and amlodipine on gentamicin-induced renal tubular toxicity in ratsEuropean Journal of Pharmacology, 2009
- Stability of Colistin Methanesulfonate in Pharmaceutical Products and Solutions for Administration to PatientsAntimicrobial Agents and Chemotherapy, 2008
- CDC/NHSN surveillance definition of health care–associated infection and criteria for specific types of infections in the acute care settingAmerican Journal of Infection Control, 2008
- Acute Kidney Injury Network: report of an initiative to improve outcomes in acute kidney injuryCritical Care, 2007
- Colistin interactions with the mammalian urotheliumAmerican Journal of Physiology-Cell Physiology, 2004
- Stability of Colistin and Colistin Methanesulfonate in Aqueous Media and Plasma as Determined by High-Performance Liquid ChromatographyAntimicrobial Agents and Chemotherapy, 2003
- In Vitro Pharmacodynamic Properties of Colistin and Colistin Methanesulfonate against Pseudomonas aeruginosa Isolates from Patients with Cystic FibrosisAntimicrobial Agents and Chemotherapy, 2001